<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">There is interest in the role of ACEI/ARB in both the overall risk of COVID-19 and the severity of lung disease with studies suggesting both the possibility of deleterious and beneficial effects [
 <xref ref-type="bibr" rid="CR49">49</xref>, 
 <xref ref-type="bibr" rid="CR50">50</xref>]. Major guideline committees have continued to advocate for the use of ACE/ARB medications in hemodynamically stable heart failure patients, hypertension, and those with ischemic heart disease [
 <xref ref-type="bibr" rid="CR51">51</xref>, 
 <xref ref-type="bibr" rid="CR52">52</xref>].
</p>
